## Cardioprotective Mechanisms: Beta-Blockers vs ACE Inhibitors ### Distinct Pathways of Benefit **Key Point:** Beta-blockers and ACE inhibitors reduce mortality in heart failure through fundamentally different mechanisms. Beta-blockers work by reducing heart rate, contractility, and myocardial oxygen demand, thereby decreasing the workload on a failing heart. ACE inhibitors work through neurohormonal antagonism (blocking the renin-angiotensin-aldosterone system) and vasodilation, reducing afterload and preventing ventricular remodelling. ### Mechanism Comparison Table | Mechanism | Beta-Blockers | ACE Inhibitors | |-----------|---------------|----------------| | **Primary Effect** | ↓ Heart rate, ↓ contractility, ↓ O₂ demand | ↓ Ang II, ↓ aldosterone, vasodilation | | **Hemodynamic Action** | Negative inotrope & chronotrope | Afterload reduction | | **Remodelling Prevention** | Indirect (via ↓ workload) | Direct (↓ collagen deposition, ↓ fibrosis) | | **Mortality Reduction** | ~34% in systolic HF | ~23% in systolic HF | | **Onset of Benefit** | Weeks to months (slow upregulation) | Days to weeks | | **Arrhythmia Protection** | Yes (↓ HR, ↓ automaticity) | Modest | **High-Yield:** Both classes reduce mortality, but through different pathways — combining them provides additive benefit. This is why the "triple therapy" of ACE-I/ARB + beta-blocker + aldosterone antagonist is the gold standard in systolic HF. **Clinical Pearl:** Beta-blockers initially worsen symptoms (negative inotropic effect) but provide long-term cardioprotection through reduction of catecholamine-mediated damage. Patients must be warned that they may feel worse before they feel better. **Mnemonic:** **ABCDE of HF** — ACE-I/ARB, Beta-blocker, Calcium channel blocker (select agents), Diuretics, Eplerenone (aldosterone antagonist). Each class addresses a different pathophysiological mechanism. [cite:Harrison 21e Ch 297]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.